Skip to main content
OpenTrials
Completed

NCT Number: NCT03583879

Using Gait Robotics to Improve Symptoms of Parkinson's Disease

This study evaluates the benefits of exoskeleton-based exercise for improving mood and cognition in people with Parkinson's disease (PD). Participants with PD will be assigned one of three treatments delivered over 8-weeks: exoskeleton exercise (experimental intervention), non-exoskeleton exercise (active comparator), and wait-list control (no treatment).

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The University of New Brunswick, Fredericton, New Brunswick, Canada

Loading trial locations.

About this study

Parkinson's Disease (PD) is a movement disorder that significantly impairs mobility and increases risk of falls. Many people with PD also experience mild cognitive impairment (MCI) and some progress to Parkinson's disease dementia (PDD). Non-pharmacologic treatments such as physical activity and exercise are known to be neuroprotective and may improve cognition, mood and overall functioning in PD, but such interventions can be challenging for individuals with PD and cognitive impairment to fully participate in. Robotic over-ground exoskeletons have the potential to overcome this barrier; however there are no scientific data yet to support the use robotic exoskeletons in the PD population or those with mood disorder and/or declining cognitive function.

This therapeutic exploratory trial will fill this gap in knowledge and provide critical data for understanding how to integrate exoskeletons into clinical practice for age-related movement disorders when cognitive decline is present. Specifically we will test if an 8-week functional exercise program (gait, balance, aerobic exercise) using the KEEOGO Rehab(tm) exoskeleton can improve mood and cognition, as well as gait and balance, compared to the same functional exercise without using the exoskeleton, and a wait-list control (no treatment).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Cognitive function score >=16 on Montreal Cognitive Assessment (MoCA)
  • Diagnosed with Parkinson's disease, Hoehn and Yahr stage 1 to 4
  • Able to walk 10 meters without stopping and without human assistance (using assistive devices such as cane or walker if normally used)
  • Waist and leg circumference and lower extremity lengths appropriate for a comfortable and safe fit in the KEEOGO device

Exclusion criteria

  • Legally blind
  • Treatment with another investigational drug or other intervention within the study period
  • New medications started within last 4 weeks
  • Skin condition that contraindicates use of orthotics or support braces
  • Lower-extremity amputation above or below the knee
  • Uncontrolled orthostatic hypotension
  • Psychiatric disorders such as schizophrenia or bipolar disorder
  • Other diagnosis that impairs gait and balance, such as, but not limited to, chronic obstructive pulmonary disease; peripheral arterial disease; vestibular disorders; cerebellar disease; cerebral palsy; muscular dystrophy; spinal cord injury; stroke or other brain injury; severe degenerative joint disease (osteoarthritis, rheumatoid arthritis, etc.)

Treatment and study plan

Exoskeleton exercise

Other

Functional exercise with a robotic exoskeleton

Standard Exercise

Other

Functional exercise without a robotic exoskeleton

No treatment

Other

Wait-list control

Primary outcomes

  1. Change in cognitive function

    Time frame: Baseline and 8 weeks

    10-item "Scales for Outcomes in Parkinson's-Cognition" (SCOPA-COG) instrument to evaluate cognitive function; Total score, range 0-43, higher scores = better cognitive functioning.

  2. Change in mood

    Time frame: Baseline and 8 weeks

    14-item "Hospital Anxiety and Depression Scale" (HADS) instrument to measure mood disorder; Total score, range 0-42, higher scores = more severe mood disorder

Secondary outcomes

  1. Change in UPDRS Mentation score

    Time frame: Baseline and 8 weeks

    "Unified Parkinson's Disease Rating Scale" (UPDRS), 4-item Section I - Mentation; Sub-scale score range 0-16, higher scores = worse symptoms.

  2. Change in UPDRS Motor score

    Time frame: Baseline and 8 weeks

    "Unified Parkinson's Disease Rating Scale" (UPDRS), 14-item Section III - Motor; Sub-scale range 0-108, higher scores = worse symptoms.

  3. Change in functional balance

    Time frame: Baseline and 8 weeks

    Brief version of Balance Evaluation Systems Test (Brief-BESTest) for balance, average of three tests.

  4. Change in self-report balance confidence (of not falling)

    Time frame: Baseline and 8 weeks

    16 item "Activity-specific Balance Confidence" (ABC) for balance self-efficacy; Total score, 0-100, is average of items scaled on 0-100% confidence in doing specific tasks without falling, higher scores = better balance confidence

  5. Change in gait speed

    Time frame: Baseline and 8 weeks

    Fast walking gait speed, average of three tests.

  6. Change in dual-task gait cost index

    Time frame: Baseline and 8 weeks

    Dual-task gait cost index (DTGC); Calculated index score (0-1) based on ratio of gait speed during normal gait minus gait speed with cognitive distractor divided by normal gait speed, average of three tests.

  7. Change in dual-task cognitive cost index

    Time frame: Baseline and 8 weeks

    Dual-task cognitive cost index (DTCC); Calculated index score (0-1) based on ratio of correct responses during sitting minus correct responses during gait divided by correct responses while seated, average of three tests.

  8. Change in six minute walk test score

    Time frame: Baseline and 8 weeks

    Distance covered with 6 min walking, average of three tests

Other outcomes

  1. Change in freezing of gait episodes

    Time frame: Baseline and 8 weeks

    6-item "Freezing of Gait Questionnaire" (FoG-Q) for measuring the impact of freezing of gait on mobility; Total score, range 0-24, higher scores = worse symptoms.

  2. Change in physical function, pain, emotional well-being, and other indicators of health-related quality of life

    Time frame: Baseline and 8 weeks

    39-item "Parkinson's Disease health-related Quality of life" (PDQ-39) survey; Total score, 0-195, higher scores = worse health-related quality of life

  3. Cumulative exercise dose

    Time frame: 2x per week for 8 weeks

    Actigraph activity monitor for quantifying cumulative energy expenditure

Sponsors and collaborators

Lead sponsor

University of New Brunswick

Other

Collaborators

  • Assistive Technology Clinic, Canada
  • Centre for Aging and Brain Health Innovation

Registry information

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jul 12, 2018
Registry last updated
Feb 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.